Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Gossamer Bio
GOSS
$75.4M
| $4.73M | ﹤0.01% |
363,600
+266,138
| +273% | +$3.35M |
|
|
LTRPA
1677
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
| $4.73M | ﹤0.01% |
2,218,621
+163,300
| +8% | +$372K |
|
1678
RLJ Lodging Trust
RLJ
$1.67B
| $4.72M | ﹤0.01% |
+499,732
| New | +$4.67M |
|
1679
State Street SPDR Portfolio Intermediate Term Corporate Bond ETF
SPIB
$11.5B
| $4.7M | ﹤0.01% |
+128,700
| New | +$4.58M |
|
|
DL
1680
DELISTED
China Distance Education Holdings Limited
DL
| $4.7M | ﹤0.01% |
544,587
+80,100
| +17% | +$592K |
|
1681
CNB Financial Corp
CCNE
$1.03B
| $4.7M | ﹤0.01% |
262,101
-71,201
| -21% | -$1.2M |
|
|
DOYU
1682
DouYu International Holdings
DOYU
$142M
| $4.68M | ﹤0.01% |
40,545
+36,925
| +1,020% | +$3.08M |
|
1683
ATI
ATI
$31.1B
| $4.68M | ﹤0.01% |
459,030
-271,162
| -37% | -$2.35M |
|
1684
Cocrystal Pharma
COCP
$15.4M
| $4.67M | ﹤0.01% |
255,944
+128,992
| +102% | +$1.58M |
|
1685
Liberty Latin America Class C
LILAK
$1.66B
| $4.67M | ﹤0.01% |
577,704
+156,363
| +37% | +$1.33M |
|
1686
Shore Bancshares
SHBI
$800M
| $4.66M | ﹤0.01% |
420,237
-14,363
| -3% | -$141K |
|
|
BPMC
1687
DELISTED
Blueprint Medicines
BPMC
| $4.66M | ﹤0.01% |
59,700
-49,500
| -45% | -$3.35M |
|
1688
Natural Gas Services Group
NGS
$490M
| $4.65M | ﹤0.01% |
741,257
-37,011
| -5% | -$215K |
|
1689
Vaalco Energy
EGY
$608M
| $4.64M | ﹤0.01% |
3,745,666
-49,976
| -1% | -$50.2K |
|
1690
Liberty Broadband Class A
LBRDA
$5.21B
| $4.64M | ﹤0.01% |
38,000
-31,500
| -45% | -$3.87M |
|
1691
United Fire Group
UFCS
$1.4B
| $4.63M | ﹤0.01% |
167,039
-20,017
| -11% | -$565K |
|
|
ITI
1692
DELISTED
Iteris, Inc.
ITI
| $4.63M | ﹤0.01% |
973,500
-10,500
| -1% | -$43.8K |
|
1693
United Airlines
UAL
$40.7B
| $4.62M | ﹤0.01% |
133,427
-988,961
| -88% | -$29.7M |
|
1694
State Street Health Care Select Sector SPDR ETF
XLV
$43.8B
| $4.61M | ﹤0.01% |
+46,100
| New | +$4.55M |
|
1695
Ovid Therapeutics
OVID
$528M
| $4.6M | ﹤0.01% |
624,109
-228,734
| -27% | -$1.07M |
|
1696
Trustmark
TRMK
$2.8B
| $4.6M | ﹤0.01% |
187,604
+150,100
| +400% | +$3.61M |
|
1697
Teekay
TK
$1.09B
| $4.6M | ﹤0.01% |
1,915,175
-486,300
| -20% | -$1.49M |
|
1698
Cognex
CGNX
$11B
| $4.59M | ﹤0.01% |
+76,856
| New | +$4.17M |
|
1699
C&F Financial
CFFI
$287M
| $4.58M | ﹤0.01% |
137,900
-3,900
| -3% | -$134K |
|
1700
CenterPoint Energy
CNP
$26.9B
| $4.56M | ﹤0.01% |
244,300
-7,441,580
| -97% | -$128M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.